EMBC · XBRL financial data

Embecta financial statements, every fiscal year

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EMBC's year ends in late September)

In millions of dollars	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue from contracts with customers	1,130	1,121	1,123	1,080
Cost of goods and services sold	355	371	388	404
Gross profit	775	750	735	677
Research and development	67	85	79	37
Selling, general and administrative	295	341	365	332
Total operating expenses	465	528	568	435
Other operating income (expense)	—	(1)	0	(1)
Operating income (loss)	310	222	167	242
Income tax expense (benefit)	33	35	(34)	41
Net income (loss)	224	70	78	95
Earnings per share, basic USD per share	3.92	1.23	1.36	1.64
Earnings per share, diluted USD per share	3.89	1.22	1.34	1.62
Weighted average shares, basic millions of shares	57	57	58	58
Weighted average shares, diluted millions of shares	57	58	58	59

Fiscal years (EMBC's year ends in late September)

In millions of dollars	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	331	327	268	226
Accounts receivable	22	17	193	146
Inventory	123	152	172	179
Total current assets	665	749	761	631
Right-of-use asset	6	23	23	20
Goodwill	16	16	16	15
Total assets	1,086	1,214	1,285	1,091
Accrued liabilities	104	118	134	99
Current portion of long-term debt	10	10	10	10
Total current liabilities	301	354	374	262
Long-term debt	1,598	1,594	1,565	1,389
Lease liability, non-current	4	15	12	10
Accumulated deficit	(577)	(541)	(499)	(446)
Total stockholders' equity	(891)	(822)	(738)	(651)
Total liabilities and equity	1,086	1,214	1,285	1,091
Common shares outstanding (cover page) millions of shares	57	57	58	59

Fiscal years (EMBC's year ends in late September)

In millions of dollars	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	224	70	78	95
Stock-based compensation	19	22	26	32
Depreciation and amortization	32	33	36	41
Net cash from operating activities	412	68	36	192
Purchases of property and equipment	24	27	16	9
Net cash from investing activities	(24)	(27)	(16)	(9)
Dividends paid	9	34	35	35
Proceeds from long-term debt	1,450	0	0	—
Repayments of long-term debt	5	10	35	185
Net cash from financing activities	(48)	(49)	(73)	(227)
Net change in cash	331	(4)	(52)	(46)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Mimedx Group	121	62	3.9*	145.9M	—	Q3 FY26 10-QSep 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
Beta Bionics	82	36	(12)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Kestra Medical Technologies	69	31	(32)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Cadre Holdings	64	203	23*	42.9M	—	Q3 FY26 10-QSep 30, 2026
Avanos Medical	66	182	(12)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.